Diaceutics (LON:DXRX) Announces Earnings Results

Diaceutics (LON:DXRX) posted its quarterly earnings results on Tuesday. The company reported GBX (3.27) EPS for the quarter, Digital Look Earnings reports. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%.

Diaceutics Trading Up 9.4%

DXRX stock traded up GBX 16 on Tuesday, hitting GBX 186. 1,307,491 shares of the company were exchanged, compared to its average volume of 202,378. The stock has a market capitalization of £157.84 million, a price-to-earnings ratio of 1,690.91 and a beta of 0.88. The company has a debt-to-equity ratio of 2.85, a current ratio of 3.43 and a quick ratio of 9.92. The business’s fifty day moving average is GBX 145.09 and its two-hundred day moving average is GBX 150.64. Diaceutics has a twelve month low of GBX 125 and a twelve month high of GBX 186.90.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reissued a “buy” rating and set a GBX 215 target price on shares of Diaceutics in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of GBX 215.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.